Abstract:The unequivocal diagnosis of Alzheimer's disease (AD) rests on histopathological evidence at brain autopsy or biopsy. The morphology of AD includes cerebral atrophy, deposition of beta A4 amyloid (A beta) (senile plaques and amyloid angiopathy), neuritic changes (neuritic plaques, neurofibrillary tangles (NFT) and neuropil threads) with formation of paired helical filaments (PHF) containing polymerized hyperphosphorylated tau protein triplet, causing disruption of the neuronal cytoskeleton with loss of synapses and neurons, with altered cortico-cortical connectivity, leading to disconnection of the cerebral cortex. Defining criteria for the morphologic diagnosis of AD is difficult due to the phenotypic heterogeneity of the disease, the absence of specific markers, and overlap of AD morphology with that observed in non-demented elderly individuals. This gray zone between normal to pathologic aging and full-fledged AD represents an important diagnostic problem and should be overcome by better standardized criteria that will allow to minimize interrater and interlaboratory variability in the diagnosis of AD. Current criteria for the morphologic diagnosis of AD are based on (semi)quantitative assessment of diffuse and neuritic plaques (NIA), exclusively neuritic plaques (CERAD), plaques and NFT in neocortex and hippocampus (Tierney et al., 1988), and staging of hierarchic spreading of neuritic AD changes (Braak and Braak, 1991); all of them have weaknesses and need to be revalidated. Multivariant analysis of an autopsy series of elderly subjects revealed significant correlations between psychostatus and both the CERAD criteria and Braak staging. Recent recommendations of the NIA-Reagan Institute for the morphologic diagnosis of AD are presented. Although the role of plaques and NFT in the pathogenesis of AD remains undetermined, clinicopathological correlative studies have shown that both lesions, if present in sufficient numbers, particularly in the neocortex, are considered the best morphological signposts for AD. Recent studies on neuron death in AD that, at least in part, appears different from classical apoptosis and may precede the symptomatic stage of AD, have shown varying results indicating only indirect relationship between DNA fragmentation and both A beta deposition and NFTs. Both these AD-typical markers appear to increase the risk of cells to degenerate, but are not the sole responsibles of the degenerative process in AD, the basic mechanisms of which remain to be elucidated.

Aß Pathology and Neuron–Glia Interactions: A Synaptocentric View

Signaling pathways regulating neuron-glia interaction and their implications in Alzheimer's disease.

Signaling Pathways Regulating Neuron–glia Interaction and Their Implications in Alzheimer's Disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Astrocytes as Neuroimmunocytes in Alzheimer's Disease: A Biochemical Tool in the Neuron-Glia Crosstalk along the Pathogenetic Pathways

Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer's disease

Inflammatory aspects of Alzheimer's disease

Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis

Neuropathology of Alzheimer's disease: a critical update

Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets

Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β-amyloid

α-synuclein in the pathophysiology of Alzheimer’s disease

Traversing Through the Trajectory of Pathogenic Astrocytes in Alzheimer’s Disease

Role of Neuron and Glia in Alzheimer's Disease and Associated Vascular Dysfunction

Targeting the Synapse in Alzheimer’s Disease

Microglial Drivers of Alzheimer's Disease Pathology: An Evolution of Diverse Participating States

Emerging Roles of Astrocytes in Neuro-Vascular Unit and the Tripartite Synapse with Emphasis on Reactive Gliosis in the Context of Alzheimer’s Disease

The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease

Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss

Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

Amyloid, Tau, Pathogen Infection and Antimicrobial Protection in Alzheimer’s Disease –conformist, Nonconformist, and Realistic Prospects for AD Pathogenesis